Key facts
- Parse Biosciences’s last known valuation is $225.0M.
- It has raised $100.3M; the latest was Merger/Acquisition ($225.0M) in Nov 2025.
- Notable investors include US National Science Foundation, Logos Capital, Marshall Wace, Soleus Capital, Vernon & Park Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Parse Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Parse Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Parse Biosciences
Developer of a single-cell sequencing technology designed to perform experiments without the need for custom instrumentation. The company offers a platform that analyzes single-nucleus transcriptomes and captures early postnatal development in the murine central nervous system, enabling researchers to increase gene detection in individual cells while reducing confounding artifacts common in single-cell sequencing experiments.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2018
- Employees
- 128
- Website
- parsebiosciences.com/
- Ownership
- Privately Held (backing)
Parse Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Parse Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Parse Biosciences in its N-PORT filings yet. We sweep new filings monthly.